Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01213199 · ClinicalTrials.gov registry record · Phase 2
Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars
A Phase 2 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01213199: Completed Phase 2 study, sponsored by Galderma R&D.
NCT01213199 is a Phase 2 study that has completed, run by Galderma R&D. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01213199, a Phase 2 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of Adapalene Gel 0.3% in the treatment of atrophic acne scars.
Primary Outcome
Grade Level: 1. Macular disease 2. Mild disease 3. Moderate disease 4. Severe disease
Interventions
- DRUG Adapalene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-03 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
What the finished NCT01213199 record still lists
NCT01213199 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which Adapalene is the first listed.
NCT01213199 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01213199 about?
NCT01213199 is a clinical study titled "Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars". The purpose of this study is to assess the efficacy and safety of Adapalene Gel 0.3% in the treatment of atrophic acne scars.
What is the current status of trial NCT01213199?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2011-03. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01213199?
The interventions under investigation include: Adapalene (DRUG).
Who is sponsoring clinical trial NCT01213199?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01213199's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia